Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Diverse study data confirm the rationale of intensive lipid-lowering

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

In a subanalysis of the FOURIER trial, treatment with evolocumab in patients with higher baseline Lp(a) resulted in non-significant greater percent reduction and greater absolute reduction of coronary events, compared to those with low baseline Lp(a).

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Modest Lp(a) lowering with PCSK9 inhibitor not enough to reduce arterial wall inflammation

Literature - Jan. 9, 2019 - Stiekema LCA et al. - Eur Heart J. 2018

In the ANITSCHKOW study, 16 weeks of treatment with evolocumab in patients with elevated Lp(a) levels, did not significantly alter arterial wall inflammation, despite lowering Lp(a) by 14%.

Consensus statement: How to identify anti-inflammatory effects of lipid-lowering therapy?

News - Jan. 8, 2019

The working group on atherosclerosis and vascular biology of the European Society of Cardiology published a position paper, which provides consensus statements on how to identify anti-inflammatory effects of lipid-lowering therapy.

Guidelines and the role of non-statin therapies for high risk ASCVD patients

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands
There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018
A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9 inhibitors: How do they work?

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 4, 2018 - John Chapman - Paris, France
Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

AHA 2018 - Chicago, IL, USA

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD
In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

Reduced all-cause mortality with PCSK9 inhibitor in patients with ACS

AHA 2018 – Chicago, IL, VS

News - Nov. 12, 2018

AHA 2018 Post-hoc analyses of the ODYSSEY OUTCOMES trial showed reduced all-cause mortality with alirocumab vs statins in patients with ACS, especially in those with LDL-c of ≥100 mg/dL at baseline.

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

AHA 2018 - Chicago, IL, USA

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA
Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

AHA 2018 Neil Stone served as vice-president of the new cholesterol guideline. He sums up the main new recommendations based on the latest evidence of recent lipid outcome trials.

PCSK9
PCSK9
PCSK9